Buddha Gurung Email and Phone Number
Buddha Gurung work email
- Valid
- Valid
- Valid
Buddha Gurung personal email
Highly motivated scientist engaged in developing allogeneic cell therapy products targeting various malignancies including liquid and solid tumors.
-
Director, Cell EngineeringCentury Therapeutics, IncPhiladelphia, Pa, Us
-
Director, Cell EngineeringCentury Therapeutics, Inc Mar 2022 - PresentPhiladelphia, Pennsylvania, Us -
Associate Director, Cell EngineringCentury Therapeutics Jan 2020 - Mar 2022
-
Group Leader, Research Cell TherapyCentury Therapeutics Jan 2019 - Jan 2020
-
ScientistThe Janssen Pharmaceutical Companies Of Johnson & Johnson Sep 2016 - Dec 2018Raritan, New Jersey, Us-Active leadership role in developing and advancing the allogeneic CAR T platform targeting hematological malignancies.-Led gene-editing efforts including use of CRISPR-Cas9, lenti- and retro-viral and AAV-mediated gene delivery for generating desired CAR T products.-Designed and conducted in vitro and in vivo experiments validating the potency and efficacy of lead allogeneic CAR T cell therapy products. -Introduced CRISPR-Cas9-mediated gene-editing technology to JBIO and successfully transferred this platform to the 'Reagent Generation' group for generating gene-specific knockout cell lines in support of antibody generation platforms. -
Research AssociateUniversity Of Pennsylvania Jan 2013 - Sep 2016Philadelphia, Pa, UsExploring the potential use of immunotherapy for targeting neuroendocrine tumors (NETs), specifically the ability of Chimeric Antigen Receptor T (CAR-T) cells to kill NET tumor cells. Hybridomas and phage display libraries were established and subsequently screened for antibodies that bind to the extracellular domains of NET-specific receptor proteins and cloned into lentiviral vector containing the 4-1-BB and CD3zeta signaling domains. The ability of these NET-specific CAR-T cells were evaluated for cytotoxicity towards target cells and suitable candidates are currently being analyzed further. -
Postdoctoral ResearcherUniversity Of Pennsylvania School Of Medicine Jan 2008 - Dec 2012Pa, UsDiscovered that the Hedgehog (HH) signaling pathway is aberrantly regulated in MEN1 tumor syndrome resulting from the loss of menin-PRMT5 mediated epigenetic repression of target genes. Importantly, our research demonstrated that administration of GDC-0449 (Erivedge), a small molecule HH antagonist, in a mouse model of MEN1 disease results in dramatic reduction of tumor cell proliferation and function. Potential use of Erivedge in human MEN1 patients along with current standard of care therapy is being explored in collaboration with the Hospital of the University of Pennsylvania.
Buddha Gurung Skills
Buddha Gurung Education Details
-
Oklahoma State UniversityBiochemistry And Molecular Biology -
Oklahoma State UniversityBiochemistry And Molecular Biology
Frequently Asked Questions about Buddha Gurung
What company does Buddha Gurung work for?
Buddha Gurung works for Century Therapeutics, Inc
What is Buddha Gurung's role at the current company?
Buddha Gurung's current role is Director, Cell Engineering.
What is Buddha Gurung's email address?
Buddha Gurung's email address is bg****@****enn.edu
What schools did Buddha Gurung attend?
Buddha Gurung attended Oklahoma State University, Oklahoma State University.
What skills is Buddha Gurung known for?
Buddha Gurung has skills like Car T Based Immunotherapy, Adoptive Immunotherapy, Antibodies, Phage Display, Hybridomas, Multi Color Flow Cytometry, Molecular Biology, Cell Biology, Western Blotting, Cell Culture, Molecular Cloning, Pcr.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial